Advertisement
Screener

Neurogene Inc. (NGNE) Beta

Neurogene Inc. (NGNE) Beta

  • Beta · 5-year monthly: Value 1.70; Formula and calculation Saved five-year monthly beta; measures historical sensitivity to the benchmark..

Beta

Overview →

Financial period ending 2026-08-31; current quote 2026-08-31. Amounts retain their stated periods and units.

MetricValueFormula and calculation
Beta · 5-year monthly1.70Saved five-year monthly beta; measures historical sensitivity to the benchmark.

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingBeta
2026-08-311.70

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.

Similar stocks

Stock NameCountryMarket CapPE Ratio
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
CorMedix Inc. (CRMD)United States$0.605B3.25
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Monopar Therapeutics (MNPR)United States$0.598B-34.82
Altimmune, Inc. (ALT)United States$0.593B-6.43
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76